Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 41 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

2%

1 trials in Phase 3/4

Results Transparency

18%

4 of 22 completed with results

Key Signals

4 with results100% success

Data Visualizations

Phase Distribution

34Total
Not Applicable (26)
P 1 (2)
P 2 (5)
P 3 (1)

Trial Status

Completed22
Unknown7
Active Not Recruiting4
Recruiting4
Withdrawn2
Enrolling By Invitation1

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 22 completed trials

Clinical Trials (41)

Showing 20 of 20 trials
NCT06503120Not ApplicableActive Not RecruitingPrimary

Nutritional Education Program for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

NCT07564947Not ApplicableEnrolling By Invitation

Impact of Ganoderma Lucidum on NRF2 Levels and Antioxidant Status in Metabolic Asscociated Fatty Liver Disease (GL-MAFLD-NRF2 Study)

NCT05558592Not ApplicableCompleted

Evaluation of the Effects of Orange Consumption on Carbohydrate and Lipid Metabolism in Subjects With MAFLD (Metabolic Associated Fatty Liver Disease)

NCT05877547Phase 2Completed

A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)

NCT04899102Not ApplicableRecruiting

Intermittent Fasting for NAFLD in Adults

NCT06445335Not ApplicableActive Not Recruiting

Prevalence of NAFLD in T2DM Patients

NCT06215131Not ApplicableCompletedPrimary

Feasibility of Immersive Virtual Reality Dietician Program in Metabolic-dysfunction Associated Steatotic Liver Disease

NCT06757348Not Yet Recruiting

Fatty Liver and Pancreatic Steatosis

NCT06445361Not ApplicableRecruiting

Prevalence of NAFLD in T1DM Patients

NCT06491342Not ApplicableCompletedPrimary

Probiotic Supplement Versus Placebo for the Treatment of Patients With Non-alcoholic Fatty Liver Disease

NCT07068191Not ApplicableRecruiting

Gepaktiv vs UDCA and Ademetionine in MAFLD With Hepatomegaly

NCT05560607Phase 1Completed

Knockdown of HSD17B13 mRNA, Pharmacokinetics, Safety, and Tolerability, of AZD7503 in Non-Alcoholic Fatty Liver Disease

NCT04761848Phase 1WithdrawnPrimary

Evaluation the Safety and Efficacy of Cilostazol in Treatment of Patients With Fatty Liver Disease

NCT04067440Completed

Characterization of the Microbiome in Peritoneum, Jejunum, Rectum and Stool

NCT06321211Active Not RecruitingPrimary

Development of a Novel Asian Mediterranean Diet and Its Acceptability in NAFLD

NCT06596109Not ApplicableRecruitingPrimary

Lifestyle Changes in Fatty Liver; Additive Effect of Honey Intake

NCT04241575Not ApplicableCompletedPrimary

Identification of Fatty Liver With Advanced Fibrosis in Type 2 Diabetes Using Simple Fibrosis Scores and Electronic Reminder Messages

NCT05855239Active Not Recruiting

Quantification of Hepatic Steatosis With Different Ultrasound Frequency

NCT06257732Not ApplicableUnknown

Different Exercise Modalities in the Treatment of NAFLD and Their Impact on Myokines

NCT05220956Not ApplicableUnknown

Impact of Time-restricted Feeding in NAFLD

Scroll to load more

Research Network

Activity Timeline